⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
1,431
Total Claims
$855K
Drug Cost
142
Beneficiaries
$6,019
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+53%
Cost per patient vs peers
$6,019 vs $3,933 avg
-11%
Brand preference vs peers
45.7% vs 51.2% avg
Brand vs Generic
54% generic
Brand: 612 claims · $819K
Generic: 727 claims · $20K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 113 | $237K |
| Empagliflozin | 71 | $119K |
| Insulin Aspart | 48 | $75K |
| Teriparatide | 14 | $72K |
| Sitagliptin Phosphate | 43 | $70K |
| Dulaglutide | 19 | $37K |
| Sitagliptin Phos/Metformin Hcl | 17 | $24K |
| Insulin Degludec | 16 | $23K |
| Insulin Degludec | 33 | $21K |
| Insulin Lispro | 11 | $15K |
| Insulin Glargine,hum.Rec.Anlog | 14 | $15K |
| Insulin Glargine,hum.Rec.Anlog | 13 | $7,529 |
| Insulin Glargine,hum.Rec.Anlog | 15 | $7,068 |
| Levothyroxine Sodium | 166 | $2,992 |
| Pen Needle, Diabetic | 19 | $2,894 |
Prescribing Profile
Patient Profile
73
Avg Age
61%
Female
1.52
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About